Drug Profile
Research programme: cancer and infectious disease therapeutics - Panacela Labs
Alternative Names: Antimycons; Arkils; Revercom; XenomycinsLatest Information Update: 02 Sep 2021
Price :
$50
*
At a glance
- Originator Childrens Cancer Institute Australia for Medical Research; Cleveland BioLabs; Roswell Park Cancer Institute; The Cleveland Clinic Foundation
- Developer Panacela Labs; Statera BioPharma
- Class Anti-infectives; Antineoplastics; Small molecules
- Mechanism of Action Androgen receptor antagonists; Multidrug resistance-associated protein 1 inhibitors; Proto-oncogene protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Parasitic infections; Prostate cancer
Most Recent Events
- 01 Sep 2021 Cytocom is now called Statera BioPharma
- 28 Jul 2021 Cytocom has been merged with Cleveland BioLabs to form Cytocom
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Russia